Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting
Authors:
Open Access
- 16 September 2024
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-8
Abstract
Antiretroviral therapy (ART) for HIV infection has evolved substantially. The development of long-acting drugs, such as cabotegravir (CAB) and rilpivirine (RPV) might improve treatment satisfaction among people living with HIV (PLWH). The real-world effectiveness of long-acting ART and its effect on patient satisfaction needs to be assessed. This study investigated antiviral effectiveness and treatment satisfaction in PLWH who switched from conventional to long-acting ART (CAB + RPV). This prospective cohort study included PLWH aged 18 years and older who switched to CAB + RPV and received the injections every 8 weeks between June 2022 and May 2023, after a 4-week oral lead-in phase. The eligibility criteria included viral suppression, absence of hepatitis B virus (HBV) DNA, and no prior RPV resistance mutations. Clinical data, including renal, lipid, and glucose biomarker levels, were monitored from the baseline to 44 weeks after switching. Treatment satisfaction was assessed using the HIV Treatment Satisfaction Questionnaire. A linear mixed-effects model was used to estimate changes in clinical data from baseline. Thirty-eight male participants were enrolled. Some participants had detectable levels of viral replication; however, all participants maintained viral suppression (HIV-RNA < 50 copies/mL) at 44 weeks and no cases of virological failure were detected. The creatinine level decreased by − 0.04 mg/dL (95% confidence interval [CI]: − 0.07 to − 0.01), lipid and glucose profiles remained stable, and treatment satisfaction increased by 6.6 points (95% CI: 2.4 to 10.8) after switching to CAB + RPV. Long-acting ART provides effective viral suppression and enhances treatment satisfaction in PLWH switching from conventional ART. Long-acting ART can improve patient well-being; however, patient selection and monitoring to prevent HBV-related complications are important.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialThe Lancet, 2017
- Efficacy and safety of nucleoside‐sparing regimen based on raltegravir and ritonavir‐boosted darunavir in HIV‐1‐infected treatment‐experienced patientsJournal of Medical Virology, 2017
- Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2017
- Characteristics of Transmitted Drug-Resistant HIV-1 in Recently Infected Treatment-Naive Patients in JapanJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority studyThe Lancet Infectious Diseases, 2016
- Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular ImmunityClinical Infectious Diseases, 2013
- A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para‐aminohippurate clearance in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal FunctionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-Infected Patients: A Retrospective Cohort Study of Japanese PatientsPLOS ONE, 2011
- Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change VersionValue in Health, 2006